PRFZ - ETF AI Analysis
Top Page
Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the last few months, indicating solid recent momentum.
Broad Sector Diversification
Holdings are spread across many sectors like technology, health care, industrials, and financials, which helps reduce the impact of weakness in any single industry.
Growing, Well-Established Fund
With several billion dollars in assets, the ETF is a sizable, established product that appears to attract and retain investor capital.
Negative Factors
High U.S. Concentration
Almost all of the ETF’s holdings are in U.S. companies, offering very limited international diversification.
Moderate Expense Ratio
The fund’s fees are not extremely high but are also not among the lowest, which slightly reduces the net return to investors over time.
Small-Mid Cap Volatility Risk
Because the ETF focuses on smaller and mid-sized companies, its share price can be more sensitive to market swings than large-cap funds.
PRFZ vs. SPDR S&P 500 ETF (SPY)
AUM2.75B
RegionNorth America
Expense Ratio0.36%
Beta1.03
IssuerInvesco
Inception DateSep 20, 2006
Dividend Yield0.84%
Asset ClassEquity
Index TrackedRAFI Fundamental Select US 1500 Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume98,742
30 Day Avg. Volume97,097
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
68.37Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1489
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PRFZ Summary
PRFZ is the Invesco FTSE RAFI US 1500 Small-Mid ETF, which follows the FTSE RAFI US 1500 Small-Mid Index. It focuses on smaller and mid-sized U.S. companies across many sectors, including technology, health care, and industrials. The fund uses a rules-based approach that looks at things like company profits and dividends instead of just size. It holds lesser-known but growing firms such as Iridium Communications and Onto Innovation. Investors might consider PRFZ for long-term growth and diversification beyond big-name stocks. A key risk is that smaller companies can be more volatile, so the ETF’s price can move up and down sharply with the market.
How much will it cost me?The expense ratio for the Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) is 0.34%, which means you’ll pay $3.40 per year for every $1,000 invested. This is slightly higher than average for ETFs because it uses an actively managed strategy based on fundamental factors rather than passive market-cap weighting.
What would affect this ETF?The PRFZ ETF, which focuses on small to mid-cap U.S. companies, could benefit from economic growth and innovation in sectors like technology and healthcare, which are heavily weighted in its portfolio. However, it may face challenges from rising interest rates or economic slowdowns, which can disproportionately impact smaller companies and cyclical sectors like consumer discretionary and industrials. Regulatory changes or shifts in market sentiment could also affect the performance of its top holdings and sector exposure.
PRFZ Top 10 Holdings
PRFZ is leaning into U.S. small- and mid-cap growth stories, with health care and tech doing most of the heavy lifting. High-flying names like 10x Genomics and Revolution Medicines have been rising sharply, giving the fund a strong biotech and life-sciences flavor, while Roivant Sciences adds to that momentum with a steadier uptrend. On the tech side, Onto Innovation and ATI are quietly powering ahead, though TTM Technologies has been more mixed, occasionally holding performance back. Energy names like Par Pacific and Crescent Energy offer diversification but play more of a supporting role than star drivers.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| 10x Genomics | 0.53% | $14.44M | $9.98B | 506.60% | 60 Neutral | |
| Roivant Sciences | 0.49% | $13.34M | $28.73B | 160.98% | 58 Neutral | |
| Par Pacific Holdings | 0.45% | $12.34M | $4.23B | 132.82% | 67 Neutral | |
| ATI | 0.44% | $11.85M | $26.09B | 136.83% | 78 Outperform | |
| Maxlinear | 0.43% | $11.65M | $7.36B | 402.51% | 60 Neutral | |
| Revolution Medicines | 0.42% | $11.33M | $40.93B | 334.05% | 52 Neutral | |
| Crescent Energy Company Class A | 0.41% | $11.13M | $4.59B | 56.00% | 66 Neutral | |
| Iovance Biotherapeutics | 0.39% | $10.60M | $4.64B | 380.66% | 50 Neutral | |
| Iridium Communications | 0.39% | $10.52M | $4.96B | 165.91% | 71 Outperform | |
| Paycom | 0.36% | $9.91M | $10.02B | 2.79% | 76 Outperform |
PRFZ Technical Analysis
Negative
―
Price Trends
54.50
Negative
53.36
Negative
50.43
Positive
Market Momentum
-0.53
Positive
38.01
Neutral
44.66
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PRFZ, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 53.89, equal to the 50-day MA of 54.50, and equal to the 200-day MA of 50.43, indicating a neutral trend. The MACD of -0.53 indicates Positive momentum. The RSI at 38.01 is Neutral, neither overbought nor oversold. The STOCH value of 44.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRFZ.
PRFZ Peer Comparison
Comparison Results
Performance Comparison
PRFZ
Invesco FTSE RAFI US 1500 Small-Mid ETF
52.76
7.82
17.40%
CGMM
Capital Group U.S. Small and Mid Cap ETF
―
―
―
TMSL
T. Rowe Price Small-Mid Cap ETF
―
―
―
JMEE
JPMorgan Market Expansion Enhanced Equity ETF
―
―
―
FSMD
Fidelity Small-Mid Multifactor ETF
―
―
―
USVM
VictoryShares USAA MSCI USA Small Cap Value Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents